Inhibition of Prostate Cancer DU-145 Cells Proliferation by Oligopeptide (YVPGP) Via PI3K/AKT/mTOR Signaling Pathway

Overview

Journal Mar Drugs

Publisher MDPI

Specialties Biology
Pharmacology

Date 2018 Sep 14

PMID 30208576

Citations 14

Authors

Xiaojuan Li

Yunping Tang

Fangmiao Yu

Yu Sun

Fangfang Huang

Yan Chen

Zuisu Yang

Guofang Ding

Affiliations

Soon will be listed here.

Abstract

We investigated the antitumor mechanism of oligopeptide (AAP-H, YVPGP) in prostate cancer DU-145 cells in vitro and in vivo. Results indicated that AAP-H was nontoxic and exhibited antitumor activities. Cell cycle analysis indicated that AAP-H may arrest DU-145 cells in the S phase. The role of the phosphatidylinositol 3-kinase/protein kinase B/mammalian rapamycin target protein (PI3K/AKT/mTOR) signaling pathway in the antitumor mechanism of APP-H was investigated. Results showed that AAP-H treatment led to dose-dependent reduction in the levels of p-AKT (Ser473), p-PI3K (p85), and p-mTOR (Ser2448), whereas t-AKT and t-PI3K levels remained unaltered compared to the untreated DU-145 cells. Inhibition of PI3K/AKT/mTOR signaling pathway in the DU-145 cells by employing inhibitor LY294002 (10 μM) or rapamycin (20 nM) effectively attenuated AAP-H-induced phosphorylation of AKT and mTOR. At the same time, inhibitor addition further elevated AAP-H-induced cleaved-caspase-3 levels. Furthermore, the effect of AAP-H on tumor growth and the role of the PI3K/AKT/mTOR signaling pathway in nude mouse model were also investigated. Immunohistochemical analysis showed that activated AKT, PI3K, and mTOR levels were reduced in DU-145 xenografts. Western blotting showed that AAP-H treatment resulted in dose-dependent reduction in p-AKT (Ser473), p-PI3K (p85), and p-mTOR (Ser2448) levels, whereas t-AKT and t-PI3K levels remained unaltered. Similarly, Bcl-xL levels decreased, whereas that of Bax increased after AAP-H treatment. AAP-H also increased initiator (caspase 8 and 9) and executor caspase (caspase 3 and 7) levels. Therefore, the antitumor mechanism of APP-H on DU-145 cells may involve regulation of the PI3K/AKT/mTOR signaling pathway, which eventually promotes apoptosis via mitochondrial and death receptor pathways. Thus, the hydrophobic oligopeptide (YVPGP) can be developed as an adjuvant for the prevention or treatment of prostate cancer in the future.

Citing Articles

Marine life as a source of anti-prostate cancer agents: an updated overview (2003-2023).

Hussain A, Sohail A, Akash M, Iqbal S, Rehman K, Imran M Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39976719 DOI: 10.1007/s00210-025-03886-6.

Natural Anticancer Peptides from Marine Animal Species: Evidence from In Vitro Cell Model Systems.

Librizzi M, Martino C, Mauro M, Abruscato G, Arizza V, Vazzana M Cancers (Basel). 2024; 16(1).

PMID: 38201464 PMC: 10777987. DOI: 10.3390/cancers16010036.

Effects of Monensin and Rapamycin Combination Therapy on Tumor Growth and Apoptosis in a Xenograft Mouse Model of Neuroblastoma.

Serter Kocoglu S, Sunay F, Akkaya P Antibiotics (Basel). 2023; 12(6).

PMID: 37370314 PMC: 10295421. DOI: 10.3390/antibiotics12060995.

Identification of Promising Drug Candidates against Prostate Cancer through Computationally-Driven Drug Repurposing.

Bernal L, Pinzi L, Rastelli G Int J Mol Sci. 2023; 24(4).

PMID: 36834548 PMC: 9964599. DOI: 10.3390/ijms24043135.

Marine Natural Products with Activities against Prostate Cancer: Recent Discoveries.

Montuori E, Hyde C, Crea F, Golding J, Lauritano C Int J Mol Sci. 2023; 24(2).

PMID: 36674949 PMC: 9865900. DOI: 10.3390/ijms24021435.

References

Stein R . Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr Relat Cancer. 2001; 8(3):237-48. DOI: 10.1677/erc.0.0080237. View

Cammer M, Gevrey J, Lorenz M, Dovas A, Condeelis J, Cox D . The mechanism of CSF-1-induced Wiskott-Aldrich syndrome protein activation in vivo: a role for phosphatidylinositol 3-kinase and Cdc42. J Biol Chem. 2009; 284(35):23302-11. PMC: 2749104. DOI: 10.1074/jbc.M109.036384. View

Esmaeili M, Moridi Farimani M, Kiaei M . Anticancer effect of calycopterin via PI3K/Akt and MAPK signaling pathways, ROS-mediated pathway and mitochondrial dysfunction in hepatoblastoma cancer (HepG2) cells. Mol Cell Biochem. 2014; 397(1-2):17-31. PMC: 5868363. DOI: 10.1007/s11010-014-2166-4. View

Morgensztern D, McLeod H . PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005; 16(8):797-803. DOI: 10.1097/01.cad.0000173476.67239.3b. View

Huang F, Yang Z, Yu D, Wang J, Li R, Ding G . Sepia ink oligopeptide induces apoptosis in prostate cancer cell lines via caspase-3 activation and elevation of Bax/Bcl-2 ratio. Mar Drugs. 2012; 10(10):2153-2165. PMC: 3497014. DOI: 10.3390/md10102153. View

Vander Heiden M, Cantley L, Thompson C . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-33. PMC: 2849637. DOI: 10.1126/science.1160809. View

Fulda S . Therapeutic opportunities based on caspase modulation. Semin Cell Dev Biol. 2017; 82:150-157. DOI: 10.1016/j.semcdb.2017.12.008. View

Zheng X, Wang Y, Liu B, Liu C, Liu D, Zhu J . Bmi-1-shRNA inhibits the proliferation of lung adenocarcinoma cells by blocking the G1/S phase through decreasing cyclin D1 and increasing p21/p27 levels. Nucleic Acid Ther. 2014; 24(3):210-6. PMC: 4026377. DOI: 10.1089/nat.2013.0459. View

Karavelioglu E, Gonul Y, Aksit H, Boyaci M, Karademir M, Simsek N . Cabazitaxel causes a dose-dependent central nervous system toxicity in rats. J Neurol Sci. 2016; 360:66-71. DOI: 10.1016/j.jns.2015.11.033. View

10.

Fulda S, Kufer M, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin K . Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 2001; 20(41):5865-77. DOI: 10.1038/sj.onc.1204750. View

11.

Tang Y, Jin S, Li X, Li X, Hu X, Chen Y . Physicochemical Properties and Biocompatibility Evaluation of Collagen from the Skin of Giant Croaker (). Mar Drugs. 2018; 16(7). PMC: 6070934. DOI: 10.3390/md16070222. View

12.

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

13.

Wu Z, Ding G, Huang F, Yang Z, Yu F, Tang Y . Anticancer Activity of Anthopleura anjunae Oligopeptides in Prostate Cancer DU-145 Cells. Mar Drugs. 2018; 16(4). PMC: 5923412. DOI: 10.3390/md16040125. View

14.

Kumar D, Shankar S, Srivastava R . Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via PI3K/Akt/mTOR signaling pathway. Cancer Lett. 2013; 343(2):179-89. DOI: 10.1016/j.canlet.2013.10.003. View

15.

Luo W, Xing X, Wang C, Hu L, Zhao G, Liu X . Effect of recombinant human platelet-derived growth factor B on cat corneal endothelial cell viability mediated by adeno-associated virus. Int J Ophthalmol. 2012; 5(4):419-23. PMC: 3428534. DOI: 10.3980/j.issn.2222-3959.2012.04.03. View

16.

Markman B, Dienstmann R, Tabernero J . Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget. 2011; 1(7):530-543. PMC: 3248125. DOI: 10.18632/oncotarget.188. View

17.

Chen K, Yeh P, Yeh K, Lu Y, Huang S, Cheng A . Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2008; 68(16):6698-707. DOI: 10.1158/0008-5472.CAN-08-0257. View

18.

Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View

19.

Kiuru P, DAuria M, Muller C, Tammela P, Vuorela H, Yli-Kauhaluoma J . Exploring marine resources for bioactive compounds. Planta Med. 2014; 80(14):1234-46. DOI: 10.1055/s-0034-1383001. View

20.

Fujita E, Jinbo A, Matuzaki H, Konishi H, Kikkawa U, Momoi T . Akt phosphorylation site found in human caspase-9 is absent in mouse caspase-9. Biochem Biophys Res Commun. 1999; 264(2):550-5. DOI: 10.1006/bbrc.1999.1387. View